The main office of represented VC is situated in the Montru00e9al. The fund was located in North America if to be more exact in Canada.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Aerpio Pharmaceuticals, Sorbent Therapeutics, Alethia BioTherapeutics. We can highlight the next thriving fund investment areas, such as Therapeutics, Medical.
Besides them, we counted 3 critical employees of this fund in our database.
The important activity for fund was in 2011. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year. The higher amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this AgeChem Venture Fund works on 4 percentage points more the average amount of lead investments.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the AgeChem Venture Fund, startups are often financed by Venture Investors, Sofinnova Investments, Novartis Venture Fund. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Venture Investors, Triathlon Medical Venture Partners. In the next rounds fund is usually obtained by Novartis Venture Fund, Venture Investors, Triathlon Medical Venture Partners.
Related Funds
Funds with similar focus
Fund Name | Location |
21st Century Fox | New York, New York, United States |
Antipodean Adventures | California, Los Angeles, United States |
Babson Capital Management | New York, New York, United States |
Conway Foundation | Arkansas, Conway, United States |
Gambit Ventures | New York, New York, United States |
Haselmeier | Baden-Wurttemberg, Germany, Stuttgart |
InvAscent | Mauritius, Port Louis, Port Louis |
Normandy Ventures | New Jersey, Skillman, United States |
Pioneers Ventures | Austria, Linz, Oberosterreich |
QBE Insurance Group | Australia, New South Wales, Sydney |
Rolesis Holdings | - |
SGPA | France, Ile-de-France, Neuilly-sur-seine |
ThirdRock Group | - |
Uni.Fund | Athens, Attiki, Greece |
Ward Ferry Management | China, Hong Kong, Hong Kong Island |
Ziffren Brittenham | California, Los Angeles, United States |
ZJU Joint Innovation Investment | China, Hangzhou, Zhejiang |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Aerpio Pharmaceuticals | $36M | 06 Nov 2013 | Cincinnati, Ohio, United States | ||
Akebia Therapeutics | $41M | 04 Jun 2013 | Cambridge, Massachusetts, United States | ||
$4M | 02 Nov 2012 | Quebec | |||
Sorbent Therapeutics | $36M | 30 Jun 2011 | Sunnyvale, California, United States | ||
Akebia Therapeutics | $22M | 26 Apr 2011 | Cambridge, Massachusetts, United States | ||
Conatus Pharmaceuticals | $20M | 11 Feb 2011 | San Diego, California, United States | ||
Sorbent Therapeutics | $21M | 13 Sep 2010 | Sunnyvale, California, United States | ||
Alethia BioTherapeutics | $9M | 07 Sep 2010 | Quebec | ||
Altair Therapeutics | $17M | 02 Feb 2010 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Aerpio Pharmaceuticals | $36M | 06 Nov 2013 | Cincinnati, Ohio, United States | ||
Akebia Therapeutics | $41M | 04 Jun 2013 | Cambridge, Massachusetts, United States | ||
$4M | 02 Nov 2012 | Quebec | |||
Sorbent Therapeutics | $36M | 30 Jun 2011 | Sunnyvale, California, United States | ||
Akebia Therapeutics | $22M | 26 Apr 2011 | Cambridge, Massachusetts, United States | ||
Conatus Pharmaceuticals | $20M | 11 Feb 2011 | San Diego, California, United States | ||
Sorbent Therapeutics | $21M | 13 Sep 2010 | Sunnyvale, California, United States | ||
Alethia BioTherapeutics | $9M | 07 Sep 2010 | Quebec | ||
Altair Therapeutics | $17M | 02 Feb 2010 | San Diego, California, United States |